Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 virologic suppression
2013-000783-29Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabotegravir, rilpivirine, abacavir and lamivudine in Human immunodeficiency virus infection type 1 (3 arms), sponsored by ViiV Healthcare. Started Feb 2014; status: completed.
02
Drugs
cabotegravirrilpivirineabacavirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-000783-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000783-29.